The interactions between the Aβ1–40 molecules species and the copper ions (Cu(II)) were intensively investigated due to their potential role in the development of the Alzheimer Disease (AD). The rate and the mechanism of the Cu(II)—Aβ complexes formation determines the aggregation pathway of the Aβ species, starting from smaller but more cytotoxic oligomers and ending up in large Aβ plaques, being the main hallmark of the AD. In our study we exploit the existing knowledge on the Cu(II)—Aβ interactions and create the theoretical model of the initial phase of the copper- driven Aβ aggregation mechanism. The model is based on the direct solution of the Chemical Master Equations, which capture the inherent stochastics of the considered system. In our work we argue that due to a strong Cu(II) affinity to Aβ and temporal accessibility of the Cu(II) ions during normal synaptic activity the aggregation driven by Cu(II) dominates the pure Aβ aggregation. We also demonstrate the dependence of the formation of different Cu(II)—Aβ complexes on the concentrations of reagents and the synaptic activity. Our findings correspond to recent experimental results and give a sound hypothesis on the AD development mechanisms.
Citation: Goch W, Bal W (2017) Numerical Simulations Reveal Randomness of Cu(II) Induced Aβ Peptide Dimerization under Conditions Present in Glutamatergic Synapses. PLoS ONE 12(1): e0170749. https://doi.org/10.1371/journal.pone.0170749
Editor: Jie Zheng, University of Akron, UNITED STATES
Received: August 8, 2016; Accepted: January 10, 2017; Published: January 26, 2017
Copyright: © 2017 Goch, Bal. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The project was supported by the Polish National Science Centre grant Preludium10 no 2015/19/N/NZ1/02021 to WG (http://www.ncn.gov.pl/) and by the Foundation for Polish Science TEAM grant no TEAM/2009-4/1 (http://www.fnp.org.pl/). Both authors received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.
Competing interests: The authors have declared that no competing interests exist.
The association between the overproduction and subsequent aggregation of Aβ peptides (Aβ1–40 and Aβ1–42) in the brain and the Alzheimer’s Disease (AD) has been documented convincingly for both the familial (inherited) and the dominant sporadic type of the disease . The extracellular deposits of aggregated Aβ (senile plaques) are the most profound hallmark of AD. The plaques, which also contain surprisingly high amounts of Cu(II) and Zn(II) ions , were initially considered to convey neurotoxicity of Aβ peptides, but later results indicated small Aβ oligomers to be key toxic species [3–6], with plaques likely serving a neuroprotective purpose as relatively safe Aβ dumps. The toxicity of oligomers comprises inhibition of the long term potentiation (LTP) of synapses, increase of neuronal membrane permeability, deactivation of glutamate receptors and eventually neuronal death [7–12].
The formation of Aβ aggregates was investigated by numerous authors. The peptides generally remain monomeric at submicromolar concentrations at neutral pH; the limiting concentrations above which precipitation occurs are 14 and 2 μM for the most frequently investigated Aβ1–40 and Aβ1–42 peptides, respectively [13–15]. Forms assumed by these peptides in the course of aggregation include oligomers, fibrils and eventually amyloid plaques [16–18]. Interactions with Cu(II) and Zn(II) ions also result in the formation of amorphous aggregates [19,20]. Among these species, the dimers are logically assumed to be the simplest aggregated Aβ forms, and thus the common initiating species for all aggregation pathways [16,17]. The Aβ dimers were indeed shown to be highly toxic [6,21] and stable at nanomolar concentrations .
Aβ1-x peptides, including Aβ1–40 and Aβ1–42 bind Cu(II) predominantly with an equimolar stoichiometry. The resulting complexes have the conditional stability constant of the order of 1010 M-1 at pH 7.4 [23,24]. The exact value for Aβ1–40 is 2.7 × 1010 M-1  and the same value is assigned to the Aβ1–42 peptide. The pleiomorphic Cu(II) binding site is localized in the N-terminal part of the peptide, with the involvement of the first two N-terminal residues (Asp1, Ala2) and imidazoles of His6, His13, and/or His14 side chains [25,26]. Kinetic studies suggest that the rate of formation of this Cu(II)-Aβ complex is close to the diffusion limit, i.e. its value can be estimated to be in the range of 109–1010 Ms-1 [27,28].
Cu(II) ions accelerate the Aβ aggregation in vitro by three to four orders of magnitude—from hours/minutes, depending on the individual Aβ1-x peptide, to seconds [29,30]. The stoichiometry of Cu(II)—Aβ interactions relevant to the aggregation phenomena is under intense debate. As mentioned above, the monomeric Aβ peptides form predominantly 1:1 complexes, with some evidence of Cu(Aβ)2 [27,31] and Cu2(Aβ) forms [26,32]. The 1:1 stoichiometry is also predominant in fibrils , although recent findings indicate that interactions between neighboring Aβ chains result in a significant increase of Cu(II) affinity in this case [17,33].
On the basis of fluorescence, stopped-flow and NMR relaxation studies Pedersen et al. suggested that the CuAβ2 complex is present transiently in solution at a very low concentration . Very recently, Branch et al.  performed a thorough stopped-flow kinetic study of Cu(II) binding to Aβ1–16 and Aβ1–40 peptides at pH 7.4, proposing the mechanism of interactions leading to the formation of the CuAβ2 complex, considered as a gateway to (Cu)xAβn oligomer formation. They also established kinetic parameters for all complex formation steps in their model of interactions (Fig 1).
Concluding from fluorescence quenching experiments, Branch et al. proposed the existence of two conformers of the CuAβ complex, where conformer I is formed initially and has a potential second Aβ binding site, whereas conformer II lies on an off-pathway (from hereafter denoted as CuAβ I and CuAβ II, respectively). The presence of two CuAβ conformers in physiological conditions was already reported in a number of structural studies [26,35,36]. The model of Branch et al. was adopted in our analysis presented below.
The initial Cu(II)/Aβ ratio is a crucial factor determining the pathway of aggregation and its final form [20,31,37]. Various scenarios were postulated for different conditions, including the formation of covalent cross–links between monomers in equimolar conditions , but in general, the Cu(II) presence leads to amorphous aggregates , perhaps due to a disruption of intermolecular β-sheets .
The oligomerization of Aβ peptides takes place in synapses, structures composed by endings of two different neurons, physically separated but functionally connected by the synaptic cleft [9,40,41]. The synaptic cleft is the venue for exchange of chemical signals between the neurons which constitute neurotransmission and neuromodulation. The synaptic cleft is flanked by non-neuronal brain cells (microglia, astrocytes), and thus can be considered as a confined biological compartment. Two of its dimensions, provided by cell membranes of the neurons (width and breadth) are relatively large (~μm), while the third, constituting the distance between the neurons (depth) is very small (~20 nm) (Fig 2B). The volumes of synaptic clefts in the human brain generally range from 2 to 20 aL . Indeed, the synaptic cleft is one of the places where Aβ is initially released upon the β-secretase cleavage of its precursor protein APP (in addition to ER, Golgi apparatus and endocytic pathway [43–45]), and consequently it is the presumable site of Aβ peptide oligomerization and metal—Aβ peptide interactions [17,46,47].
In systems where the volume of the chemical reaction compartment is small and/or substrate concentrations are very low, the probabilistic nature of chemical reactions, resulting from the stochastic occurrence of intermolecular collisions, may play a significant role. When the average concentration of a chemical species corresponds to only a few molecules, the intrinsic noise (unpredictability of evolution of the system of interacting molecules) becomes a substantial or sometimes even dominant factor in the system. This question was already addressed in several papers [48–50], but not in the context of chemical reactions taking place in extremely small volumes, such as synaptic clefts. The acknowledged method of deriving theoretical prediction for noise–driven systems adopted in this work is to formulate the adequate mathematical model, given in terms of probabilistic functions and described by the well-established Chemical Master Equation (CME) . The Gillespie Algorithm, popularized by Dan Gillespie in the late 1970-ies, is an algorithm for acquiring exact sample trajectories for the evolution of such systems.
Our choice of CME model was dictated by the fact that such approach constitutes a formal way to incorporate a randomness arising from the aforementioned discreteness of our system. Such approach is distinct from other simulations, which adopt Molecular Dynamics (MD) to investigate the conformation of Aβ aggregates (reviewed in ) or use theoretical models described in terms of differential equations (DE) to study the kinetics of the aggregation process [53,54]. Our model shares some similarities with the later approach. First of all, to our best knowledge it is the first model to quantitatively estimate complex formation upon interactions of Aβ peptides with Cu(II) ions. Secondly, instead of tracking the change in the concentration (which is characteristic for DE) our model calculates the distribution of probabilities for all possible outcomes of the reactions at every time point. The strength of such modeling technique lies in fact that, apart from the general kinetics of the model, we estimate the intrinsic variability (stochastic noise) of the system and incorporate the dependence of the system evolution on the volume of the synaptic cleft. Such approach is limited by a lack of structural information (on the single–molecule level) and by not taking into account the dependence on morphological shape of the cleft (on the level of the whole system).
Straightforward calculations lead to the apparently overlooked, but crucial conclusion that the attoliter volume of synaptic clefts is so small that micromolar or nanomolar concentrations correspond to very low or even fractional (thus non-physical) numbers of molecules, as illustrated in Fig 3.
(A) The number of Aβ1–42 molecules corresponding to the aggregation concentration (2 μM) in the volume range of synaptic clefts. (B) The correlation between the synaptic cleft volume and the formal concentration corresponding to the presence of just one molecule of a given species.
The subnanomolar concentrations reported in the literature for Aβ peptides in the brain are based on the cerebrospinal fluid analyses (CSF) [13,14] and on the interstitial fluid microdialysis . As illustrated in Fig 2B, such concentrations are irrelevantly low for synaptic clefts. Consequently, it only takes a dozen or less molecules to reach the concentration sufficient for spontaneous Aβ aggregation as observed in test tube experiments (Fig 3A).
A vast number of studies showed that the accumulation of Aβ peptides in AD affected patients is accompanied with the decreased levels of Aβ1–42 in CSF [55,56] which in turn is associated with the formation of amyloid plaques . This is consistent with findings that the level of Aβ oligomers is elevated in AD . Moreover, the cleavage of APP is amplified due to increase in the activity of the β–secretase protein , with not a fully defined role of presenilin [60,61]. On the level of a single synapse the following picture emerges—in a healthy brain the numbers of Aβ molecules oscillate around one molecule, which already constitutes a reported physiological concentration. In AD the presented observations suggest that this numbers are probably higher, firstly because the increased Aβ production directly elevates the numbers of molecules in the synapse and secondly because the significant presence of soluble oligomers automatically requires an adequate amount of Aβ monomers.
As stated above, the Aβ aggregation is accelerated by the presence of Cu(II) ions. The release of Cu(II) ions from the postsynaptic terminal is correlated with the neurotransmitter release after excitation of the presynaptic ending. Cu(II) ions can reach a peak concentration in the synaptic cleft as high as 100–250 μM [62–64]. Then they are cleared rapidly (on a millisecond timescale) to help the synapse recover for the next impulse. The Cu(II) uptake is mainly due to the hCtr1 membrane copper receptor  present inside the synaptic cleft (on neurons) and outside the cleft (on glial cells) and to metallothionein-3 in the extracellular space . The reported levels of Cu(II) ions in CSF are on the level of 0.2–0.5μM [67,68], which corresponds to only 1–6 ions inside the synaptic cleft, depending on the volume(Fig 3), whereas the very high, but temporal elevation of the Cu(II) concentration results from the release of approximately 300 ions in a typical (5aL) synapse. The additional observation is that the presence of one ion constitutes a minimal (nonzero) concentration, i.e. 83 nM for largest synapses (20 aL) and 830 nM for the smallest ones (2 aL).
In this work we investigated the possible course of the very first step of Aβ aggregation, i.e. the Aβ dimer formation, and the potential role of Cu(II) ions in this process. We simulated different scenarios of Cu(II) release into the synaptic cleft, tracked the formation of dimers and checked how the behavior of the system depends on concentrations of reagents and volumes in which the modeled process takes place. In order to account for effects arising from a small number of interacting molecules we applied the stochastic description which helped us reveal the importance of the probabilistic factor in the modeled process. In our analysis some arbitrary choices regarding concentrations and timescales had to be made. In particular, we performed calculations for the range of 1 to 10 Aβ molecules, which correspond to high nanomolar to low micromolar concentrations, depending on the synaptic cleft size (see Fig 3). This range covers the predicted number of molecules in both healthy and pathological conditions. The number of Cu(II) ions varied depending on the considered scenario. Also two distinct time scales were analyzed—4 ms and 20 s. The shorter timescale of 4 ms corresponds to the average time of signal transmission and therefore determines the interval between consecutive Cu(II) releases. The longer timescale was chosen in such a way that the Aβ dimerization induced by Cu(II) ions could be covered, according to the set of reaction rates presented in the model of Branch et al. implemented in our work .
In our research we applied a space–independent stochastic model described in terms of states and their probabilities. Every state was treated as a set of numbers of molecules of all species in the model. To every state we assigned a probability that the model is in this particular state at a given time t. The evolution of these time dependent probabilities was described by a set of ordinary differential equations derived from the law of mass conservation (CME). A brief account of assumptions and details of the CME approach is given in Supplementary Information, Section 1 (S1 Text). An example of solutions of CME is given in Fig 4. The equations were solved numerically using built-in solvers of the Wolfram Mathematica 9 environment.
The presented probability functions describe the model of oligomerization of the Aβ1–42 peptide when 10 Aβ1–42 molecules are present initially in the 5 aL volume.
Average times until the appearance of a given complex were calculated from a set of algebraic equations relating the times of passage between states to the occurrence of a particular group of states, defined by the first appearance of a molecule of the complex of interest. Such set of equations can be visualized by a corresponding graph, in which vertexes are possible states and edges are weighted by average times of passage between states. An example of such graph with the aforementioned states highlighted in red is presented in Fig 5.
Every state is defined by numbers of three kinds of molecules: Aβ monomers, CuAβ I complexes and Cu(Aβ)2 complexes (here described as indexes of the graph nodes). The system when initially there are 3 Aβ molecules and 2 Cu(II) ions is presented.
The calculations were first performed for the dimerization of the Aβ1–42 peptide alone, and followed by calculations on the Cu(II)-dependent dimerization according to the experimental model by Branch et al. . Three synaptic states: resting state, excited state and strongly stimulated state and four possible scenarios based on these states were considered. In all calculations the number of Aβ molecules ranged from 1 to 10. In the resting state the number of Cu(II) ions also ranged from 1 to 10 and no additional fluxes were included. In the excited state we modeled a single event of Cu(II) ions release, which resulted in an immediate elevation of Cu(II) concentration, followed by a time dependent decrease due to the diffusion of Cu(II) ions outside the cleft (S2 Text). In the third model two scenarios were considered: (a) a repetitive activation followed by a number of releases of Cu(II) ions in regular intervals and (b) a strong excitation immediately followed by a series of succeeding Cu(II) releases. A summary of these computational models of synaptic states is shown in Table 1.
We performed our analysis for four physiologically realistic volumes– 2, 5, 10 and 20 attolitres, covering most of this size variability .
As stated above, the numbers of molecules interacting in systems studied here are not sufficient for the usage of average parameters, such as concentration, to describe their behavior. Instead, the stochastic calculations were performed. In their course, we determined the distribution of possible outcomes of reactions and their probabilities, depicting an inherent noisiness of the systems. In order to give a uniform characterization of noise, we define relative standard deviation (RSD) as its measure:
RSD shows a relation of variability in a given parameter to its expected (average) value. This measure can be determined for each reacting species separately at every time point. In our work we will discuss only the RSD values for the Aβ dimers (both with and without Cu(II)), because they are in the center of our attention as an entry to the aggregation pathway and likely toxic species on their own.
RSD can be interpreted as a measure of uncertainty defined as a fraction of the expected value. While it is a reasonable measure of noise, it always has to be analyzed in respect to the expected values, since the systems where expected values are close to zero are characterized with the increasing RSD values (S3 Text).
The parameters yielded by our calculations covered the evolution of the average number of molecules, its RSD and the average time until the first appearance of both CuAβ conformers and the CuAβ2 complex detected by Branch et al .
The average time until the appearance of a given complex were chosen to monitor the system evolution, because of the irreversible nature of Aβ dimerization and because the eventual toxic processes are evoked by these dimers. The latter occurs beyond the kinetic system studied. Within the framework of this study, we can only investigate the ability of the system to generate toxin, on the assumption that its further molecular interactions do not form a feedback loop with the system.
Aβ dimerization in the absence of Cu(II)
In the first stage of our calculations a simple model of Aβ1–42 aggregation in the absence of Cu(II) ions was taken into account. The model of dimer and trimer formation was adopted from work of Garai and Frieden , who determined the rate constants of formation and dissociation for these species. The value of dimerization rate constant from their work (990 M-1s-1) is consistent with determinations made in other studies [53,54] as well as estimations based on the data for the n-mer formation . The rate of oligomerization is generally higher than the mean rate of aggregation. This probably reflects the change of association mechanism upon the formation of larger aggregates .
The time until dimerization calculated by us is of the order of minutes and can vary to a large extent depending on conditions. Also the average number of dimers depends on both the initial number of Aβ molecules and the volume (Fig 6A). The fraction of the dimerized peptide increases steadily in the course of this irreversible process, proportionally to the initial number of molecules, and after 20 s situates itself in a wide range between 0.3% (for 20 aL) and 21% (for 2 aL) (S1 Table). The interval of 20 s was too short to observe a substantial number of trimers (fraction of trimers < 0.05% in all cases) and they were excluded from further analysis. The RSD is in the wide range from 0.8 (2 aL, 10 Aβ molecules) to 18.52 (20 aL, 2 Aβ molecules) and for the range of initial conditions that we took into account, its median is 2.97. The relatively high RSD values result from the fact that the average numbers of Aβ2 dimers are less than one, which boosts the values for RSD (S3 Text). In this model the formation of dimers is a slow process progressing steadily, but with a significant uncertainty of outcome for a given numerical experiment (noise) involved (Fig 6B).
(A) The expected fraction of Aβ2 dimer after 5 min in a 2 aL (magenta), 5 aL (blue), 10 aL (red) and 20 aL (green). (B) The expected number of Aβ monomers (red) and Aβ2 dimers (blue) together with their standard deviations for a case when 10 Aβ molecules are present initially in a 5 aL volume.
The Cu(II)-induced Aβ dimerization in the resting state of the synapse
For this state two cases are considered: (i) when the number of Cu(II) ions is equal to or larger than that of Aβ molecules (Cu(II) ≥ Aβ) and (ii) when it is lower (Cu(II) < Aβ).
Cu(II) ≥ Aβ.
The presence of Cu(II) ions changes the ability of the Aβ peptide to dimerize drastically, but this effect depends on the Cu(II)/Aβ ratio. In cases when Cu(II) ≥ Aβ, the CuAβ I and CuAβ II complexes become the major components of the analyzed system (Fig 7A). Due to a high complex stability, its formation is limited practically only by the Cu(II) availability. The complex formation is very fast—after only four milliseconds 70–90% of total Aβ becomes bound in the CuAβ I complex, depending on the ratio of reagents (S2 Table). Such a short time results from the proximity of the ligands (i.e. small volume of synaptic cleft) and a very high association constant, close to the diffusion limit [27,28]. The chance of CuAβ2 appearance is close to zero (~ 5% in most favorable cases, ~ 1% in general) in the short timescale of 4 ms, which is the time of a single synaptic excitation. Similar values are taken in a longer timescale of 20 s (S3 Table), which corresponds to the expected time of CuAβ2 appearance under more favorable conditions (see below).
The expected number of Aβ monomers (blue), CuAβ I (brown) and CuAβ2 (red) according to the model of Branch et al.  together with their standard deviation for a case when 10 Aβ and 10 Cu(II) ions (A) or 10 Aβ and 5 Cu(II) ions (B) are present initially in the 5 aL volume. The time scale is logarithmic. CuAβ II complexes are omitted for the sake of clarity of presentation.
The RSD values for CuAβ2 complex ranged from 3 to 57, but the highest RSD values corresponded to the lowest expected values (S3 Text) and consequently the CuAβ2 presence in the system was negligible.
Cu(II) < Aβ.
A different picture appears when Aβ molecules are in excess over Cu(II). In such conditions, the CuAβ I formation is limited by the number of Cu(II) ions while the presence of free Aβ monomers allows for the eventual formation of CuAβ2 complexes. The time scale of formation of CuAβ and CuAβ2 complexes differs by three orders of magnitude. In the millisecond timescale the system behavior is similar to the former case—all Cu(II) ions bind to Aβ in a 1:1 stoichiometry forming the CuAβ I complex (Fig 7B). The formation of CuAβ II takes more time, in the range of 0.1 to 1 s. Its appearance is connected with the widening of the standard deviation range for CuAβ I (Fig 7). It also lowers the probability of the dimer formation, due to the fact that it is a dead end in the aggregation pathway presented in Scheme 1.
The average time until the formation of CuAβ2 is relatively long—seconds, but it still much faster than the formation of Aβ2 dimers. The yield of this process, measured by the Aβ percentage, is the highest when the Cu:Aβ ratio is exactly 1:2, reaching 30%—70% in a typical (5 aL) synaptic cleft (Fig 8). A strong volume dependence can be observed for this process. In a 2 aL cleft the total Aβ in the CuAβ2 dimer ranges from 58% to 87%, whereas in a 20 aL cleft it does not exceed 35%. (Fig 9, S6 Table).
Results are presented for initial numbers of Aβ molecules ranging from 2 (violet) to 10 (red). The results for CuAβ2 in other volumes in are presented in S3 Table and results for CuAβ I after 4 ms in S5 Table.
The volume of synaptic cleft was 2 aL (magenta), 5 aL (blue), 10 aL (red) and 20 aL (green).
The RSD for the CuAβ2 complex was calculated in a longer timescale of 20 s where the probability of its formation is sufficient for reliable estimations. In such cases, the RSD ranged from 16% to 139% for a typical 5 aL synaptic cleft (S3 Table). The highest values occurred for cases where there were only a few molecules in the system, e.g. two Aβ peptides and one Cu(II) ion (139%) or three Aβ peptides and one or two Cu(II) ions (87% in both). In general, the level of noise was moderate (median of 28%) and higher in cases closer to the 1:2 stoichiometry (median of 49% for cases where the stoichiometry was exactly 1:2). On the other hand, a strong volume dependence could be noticed. Because the extent of dimer formation was higher in smaller synapses, with a simultaneous decrease of the noise, the RSD values were higher for larger volumes (S4 Table). As a result, 2 aL synapses where characterized by small noisiness (median of 12%), but in the larger ones the level of noise became significant (median of 50% and 84% for 10 aL and 20 aL, respectively). In general, the noisiness of the system is high, i.e. highly variable reaction outcomes can be expected from one synapse to another.
The Cu(II)—induced Aβ dimerization in the excited state of the synapse
In the next step we reconstructed the situation of release of a large quantity of Cu(II) ions upon the synaptic excitation. The number of Cu(II) ions in calculations ranged from 50 to 500, which corresponded to physiological concentrations reported, while taking actual synaptic cleft volumes into account. In this case the initial overflow of the system with Cu(II) ions quickly becomes neutralized by their steady efflux due to diffusion. The diffusion coefficient was estimated for the known physical parameters of the synaptic cleft fluid from the Stokes-Einstein equation as 3.45 × 10−10 m2s-1. This value is in a good agreement with experimental values recorded in low viscosity media (see S2 Text for details). The time window when Cu(II) ions are present in high numbers in the system is narrow, on the order of 100 ms, but it is sufficient for the CuAβ I and CuAβ II formation. Consequently, the Cu(II) ions stay in the cleft sufficiently long to totally saturate the pool of Aβ present in the system (Fig 10).
The expected number of Aβ monomers (blue), CuAβ I (brown) and CuAβ2 (red) according to the model of Branch et al.  together with their standard deviations in the case where 10 Aβ molecules are present initially in the 5 aL volume after the release of 50 Cu(II) ions. The time scale is logarithmic.
The level of saturation exceeds 99% in all situations in the 4 ms timescale (S5 Table). The level of formation of CuAβ2 in a longer time perspective is in general low, but strongly depends on conditions. Predictably, the most favorable cases are when the smallest number of ions is released (50 in our calculations), the volume is small and the total number of Aβ molecules is high. In the extreme case (2 aL, 50 ions released), on average up to 51% of Aβ is present as dimers after 20 s. In general, in case of 50 released ions the values range from 10 to 20% (for 10 aL and 5 aL correspondingly; S6 Table). When higher Cu(II) amounts are present, the Aβ peptides become caught in CuAβ I and CuAβ II complexes and the fraction of Aβ present as CuAβ2 is on the level of just a few percent (Fig 11). In general, these calculations indicate that a single synaptic excitation tends to prevent the formation of CuAβ2, but not without exceptions.
Results are presented for release of 50 (blue), 100 (red), 200 (green) and 500 (orange) Cu(II) ions. The results for CuAβ2 in other volumes are presented in S6 Table.
The initial system overload with Cu(II) ions determines its behavior. Such situation drastically eliminates any possible noise, because initially all of the Aβ molecules bind the Cu(II) ions. The time on the level of seconds is required until any CuAβ complex will dissociate and a CuAβ2 complex may form. Only after this initial interval the noisiness of the system starts to become significant. The RSD values for CuAβ2 are relatively high in the 20 seconds timescale. The lowest RSD value is 0.34 for the case, when the potential dimer formation is strongest (10 Aβ molecules and 50 Cu(II) ions released into the 2 aL volume). In general the RSD is high, about 1.36 to 2.93 for cases when the CuAβ2 presence is noticeable (over one molecule on average), with the median of 2.52 for all cases. Due to the diffusion the starting number of Cu(II) ions quickly decreases to less than 10 after 2 s and typically less than one after 20 s (Figure A in S2 Text). In 20 aL and in cases when 10 Aβ molecules are present in the system the level of noise is therefore comparable to the noise observed in the resting state.
The Cu(II)-induced Aβ dimerization after strong synaptic stimulation
Finally we aimed to model conditions present in the synaptic cleft during an intense stimulation. Two specific modes of such stimulation were considered. In one a chronic stimulation was applied over the interval of 20 s, with excitation, and consequently Cu(II) release occurring every 2 s (Fig 12). In another the strong excitation was composed of a train of impulses which led to a series of ten outbursts of Cu(II) ions in 4 ms intervals. In both cases the continuous release resulted in a large pool of Cu(II) ions remaining in the synaptic cleft for an extended period of time.
The expected number of Aβ monomers (blue), CuAβ I (brown) and CuAβ2 (red) according to the model of Branch et al.  together with their standard deviation in the case when 10 Aβ molecules are present initially in the 5 aL volume after a series of regular releases of 100 Cu(II) ions every 2 s. The moments of Cu(II) release are marked by the dashed lines. The time scale is logarithmic. Results for the other mode of strong stimulation are analogous (S10 Table).
Consequently the second mode becomes an extreme case of the first one. Aβ molecules become completely saturated with Cu(II) ions and the presence of CuAβ2 is negligible (~ 1% in the most favorable cases). The immediate formation of CuAβ I complexes determines the system, as there is not enough time (in repetitive stimulation, S8 Table) or there is too much Cu(II) available (in the strong stimulation mode) to form the dimers (Fig 13, S10 Table). In consequence, the average extent of CuAβ2 formation is negligible, making the respective RSD values meaningless. In other words in this model the system behaves in a deterministic way, i. e. is fully predictable and can be described correctly using the formalism of rate and equilibrium constants.
The synaptic cleft is a key site of release of Aβ peptides as a result of proteolysis of the APP protein. Our analysis demonstrated that the specific conditions present in this very small extracellular compartment, such as co-localization and proximity of potential reagents in the constrained space, result in a behavior of reagents that is different from that observed in bulk experiments (test tube scale). The main difference arises from the fact that in extremely small volumes of synaptic clefts (2–20 aL) concentrations, considered to be physiologically relevant for both Aβ peptides and Cu(II) ions correspond to just a few molecules/ions (for μM concentrations) or no molecules at all (for nM concentrations). As shown in Fig 3, the 1 μM concentration in 20 aL translates to 12 molecules, and one molecule in 2 aL constitutes a 833 nM concentration.
As explained above and illustrated in Fig 3, in such small volumes the generally accepted concept of concentration as a measure of presence of chemical species breaks down. The stochastic description must be used for chemical reactions, as the presence of just a few molecules of interacting species stipulates the probabilistic nature of their interactions. A high intrinsic noise (randomness of the reaction outcome) produced by these circumstances leads to sporadic occurrence of highly unlikely events, which can alter the evolution of the system in time. Consequently, using concentrations of Cu(II) ions and Aβ peptides alone in the kinetic analysis, one cannot predict the fate of the evolving system. The probabilistic factor must be taken into account. This approach can be explained using the results presented in Fig 14 as an example. We performed 100 independent calculations of the outcome of Cu(II)—induced dimerization after 20 s, for the initial 10 Aβ molecules and 5 Cu(II) ions in the 20 aL volume. The observed number of CuAβ2 complexes varied from 0 to 4 in individual calculations, with each of these possibilities having substantial probabilities of occurrence. This spread of results can be therefore described as a distribution of the potential outcomes (Fig 14B) defining the level of noise.
(A) Sample outcomes of 100 simulations in the time scale of 20 s in case of 10 Aβ and 5 Cu(II) in 20 aL. Color codes the number of CuAβ2 complexes (0—black, 1—yellow, 2—blue, 3—red, 4—green). The results are ordered by the number of a trial calculation. (B) Distribution of numbers of CuAβ2 complexes.
The other factor contributing to the variability of the Cu(II)—Aβ system is the size of the synaptic cleft, which can vary from 2 aL to 20 aL. As a consequence, the same ensemble of molecules may yield different quantities of reaction products, depending on the volume. In our work we report the average outcomes (correlated with the results from macroscopic experiments) in various conditions, in addition to the approximate level of noise.
Experimental studies on the aggregation of Aβ peptides established a tentative consensus regarding the particular neurotoxicity of small oligomers, including dimers [6,71]. It is also clear that the aggregation pathway is defined at the very first steps of the process and is determined by the initial conditions [16,20]. The role of Cu(II) ions as factors accelerating the Aβ aggregation has also been studied thoroughly by several research groups. We focus on the pathway to CuAβ2 complexes, being dimers par excellence and compare it with the apopetide dimerization. Our calculations are based on the most recent self-consistent set of kinetic data published by Branch et al. . Their model of interactions is sufficiently complete to provide a basis for qualitative description of the systematic noise, which arises from the small number of interacting Aβ molecules and Cu(II) ions and therefore is an inherent part of all possible mechanisms. One has to stress, however, that our approach is technically universal and can adopt any new or expanded kinetic models of interactions. Our analysis can be treated as extended discussion of results of Branch et al., or as a Gedankenexperiment in which we try to look at consequences of a certain set of experimental data. Its most obvious limitations are listed in the last paragraph of the discussion.
The first important result of our analysis is that the size of synaptic cleft alone forces the Aβ peptides to aggregate spontaneously. The concentration of 2 μM, which is sufficient for the Aβ42 peptide to aggregate in an isolated system, can be achieved by merely three Aβ42 molecules in the smallest (2 aL) synaptic clefts, and 24 molecules in the largest ones (20 aL). The unassisted Aβ aggregation is, however, slow. The time required for the formation of Aβ dimer (~3 min) is an order of magnitude longer than that required for the corresponding CuAβ2 dimer to form (~ 20 s), not to mention the formation of monomeric CuAβ I complexes, which is practically immediate (Fig 15).
The dimerization time depends strongly on concentrations and the volume of the cleft, but in every case it is significantly longer than the formation of Cu(II) complexes. Taking into account the limited synaptic volume and rates of neuronal firing, associated with the regular release of a variety of factors interacting with Aβ peptides, including Zn(II) and Cu(II) ions, one can risk an opinion that the aggregation of Aβ peptide alone is too slow to be significant even in the confinement of the synaptic cleft. One can therefore speculate that the metal free Aβ aggregation may only occur outside the active synaptic cleft.
We focused on the effect of Cu(II) ions due to their known association with the Aβ toxicity . Results of our analysis are consistent with prior experimental papers on the role of Cu(II) ions in Aβ oligomerization and show that their presence drastically affects the propensity of the system for dimerization. The Cu(II)/Aβ ratio is the most influential factor here, yielding a very sharp dependence of the probable outcome of reactions. Whenever the number of Cu(II) ions is equal to or higher than that of Aβ molecules, the CuAβ I complexes are formed nearly immediately (within milliseconds). The Cu(II) availability is the only limiting factor here. This situation leads to a specific pathway culminating in amorphous aggregates, which are thought to be generally non-toxic [37,73]. In the alternative case of Aβ excess, the CuAβ2 complex can also be formed. The formation of CuAβ2 is most efficient when the Cu(II):Aβ ratio is exactly 1:2, that is under the sub-equimolar conditions studied by Pedersen and Smith [20,74]. This would explain the observed differences in aggregation pathways and strengthen the hypothesis that the formation of CuAβ2 promotes formation of toxic forms of Aβ [31,37]. The activity of the synapse is crucial in this context. The release of relatively high numbers of Cu(II) ions immediately changes the balance of the process, shifting it towards CuAβ I and CuAβ II complexes. This effect is not neglected by a high rate of clearance of Cu(II) from the cleft. Due to a relatively high affinity of Aβ peptides for Cu(II) ions, a nearly total saturation of the peptide takes place. Rephrasing, Aβ-bound Cu(II) ions remain in the system and a situation similar to that of the initial high Cu(II) excess can be observed. A series of impulses and consecutive releases of Cu(II) redirect the system towards the “Cu(II) excess” pathway with a simultaneous elimination of randomness of the reaction outcome (noise). Reduction of the noise is illustrated by narrowing down of the outcome distribution, which results from the rapid drop in the probability of CuAβ2 appearance (Fig 16). A high activity of the synapse is therefore redirecting the Aβ chemistry from aggregation towards the diffusible monomeric Cu(II) complex formation. We cannot state whether this effect decreases cytotoxicity or merely redirects is towards the oxidative pathway. Anyway this finding correlates the high synaptic activity with the decrease of the level of Aβ aggregation, which albeit simplistically, agrees with the known positive correlation of mental activity and resistance to Alzheimer’s disease.
Presented distributions describe the case of 10 Aβ molecules in 20 aL: left—in resting state with 5 Cu(II), middle—upon a single release of 100 Cu(II), right—upon a train of releases of 100 Cu(II) each.
According to our results, the main feature of Cu(II) dependent Aβ dimerization inside the synaptic cleft is its probabilistic nature. Small numbers of interacting molecules result in a wide range of possible reaction outcomes. Moreover, rare events have to be taken into account. When the system is not overloaded with Cu(II) ions, it is characterized by a high noise (Fig 16) which can alter the macroscopic evolution of the Cu(II)—Aβ system in a similar way as the stochastic factor controls the nucleation of Aβ1–40 peptide . If the pathology of AD arises from a spontaneous formation of toxic and stable dimers, then the occurrence of the disease would have a stochastic nature, time (i.e. age) being necessarily a major risk factor. Moreover, the Cu(II) targeting therapies could be extremely difficult. A total depletion of synaptic Cu(II) is nearly impossible (and would be extremely harmful) and our results suggest that a partial Cu(II) depletion might actually accelerate rather than eliminate the neurotoxic Aβ dimer formation.
The level of noise varies also between synapses. Volumes of synaptic clefts are smaller in small synapses and are consequently characterized by more efficient interactions, due to the higher average proximity between the ligands (Fig 9). As such, their noisiness is lower when compared with the larger ones. On the other hand the size of the cleft corresponds to the size of dendritic spines. The mature and more stable spines are dominant in adult people and are characterized by larger sizes [42,76]. Our model suggests that such stabilization of dendritic spines distribution may enhance the probability of rare events, including the formation of CuAβ2 complexes.
Summarizing, in a properly functioning synaptic cleft, the accessibility of Cu(II) ions for Aβ binding should drive the aggregation towards the non toxic pathway, but the probabilistic nature of the reactions, especially in inactive synapses may bring the whole process on potentially more dangerous trails.
As already stated above, the kinetic model of Cu(II)-dependent Aβ peptide aggregation adopted and discussed above is of course very simplistic, largely by necessity. While the presence of multiple factors affecting the availability of Aβ peptides and Cu(II) ions is known, the quantities and kinetic properties of these factors (e.g. Cu(II) binding proteins) remain to be established. Thus, they could not be presently included in our model. Another important feature is the multiplicity of Aβ peptide forms. In this respect, we would like to mention the Aβ4–42 peptide, which is highly abundant in the brain [77–80]. We recently demonstrated this peptide to be a much stronger Cu(II) chelator than the Aβ1–40 or Aβ1–42 peptides (by a factor of 3000), and a likely physiological target for Cu(II) ions [81,82]. Its presence in the synaptic cleft may prevent Cu(II) interactions with the Aβ peptides considered in the kinetic model. The Aβ4–42 peptide also yields apparently toxic aggregates , but the effect of Cu(II) ions on their formation and properties remains to be established. One way of further development of our model will be to include Cu(II) binding properties of such potentially important molecules as soon as appropriate kinetic data become available.
S1 Table. Dimerization without Cu(II).
Average fraction of total Aβ bound as a Aβ2 complex [%].
S2 Table. Resting state.
Average fraction of total Aβ bound as a CuAβ I conformer [%] after 4ms.
S3 Table. Resting state.
Average fraction of total Aβ bound as a CuAβ2 complex [%] after 20 s.
S4 Table. Resting state.
RSD of CuAβ2 complex after 20 s.
S5 Table. Excited state.
Average fraction of total Aβ bound as a CuAβ I conformer [%] after 4ms.
S6 Table. Excited state.
Average fraction of total Aβ bound as a CuAβ2 complex [%] after 20 s.
S7 Table. Excited state.
RSD of CuAβ2 complex after 20 s.
S8 Table. Regular long excitation.
Average fraction of total Aβ bound as a CuAβ2 complex [%] after 20 s.
S9 Table. Regular long excitation.
RSD of CuAβ2 complex after 20 s.
S10 Table. Short strong excitation.
Average fraction of total Aβ bound as a CuAβ2 complex [%] after 20 s.
S11 Table. Short strong excitation.
RSD of CuAβ2 complex after 20 s.
We thank Dr. Simon Drew (University of Melbourne, Australia) for critical reading of the manuscript and insightful comments.
- Conceptualization: WG WB.
- Data curation: WG.
- Formal analysis: WG.
- Funding acquisition: WG WB.
- Investigation: WG.
- Project administration: WB.
- Resources: WB.
- Software: WG.
- Supervision: WB.
- Validation: WG.
- Visualization: WG.
- Writing – original draft: WG WB.
- Writing – review & editing: WB.
- 1. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson P V, Bjornsson S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature [Internet]. 2012 Jul 11;488(7409):96–9. Available from: http://www.nature.com/doifinder/10.1038/nature11283
- 2. Lovell M., Robertson J., Teesdale W., Campbell J., Markesbery W. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci [Internet]. 1998 Jun;158(1):47–52. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022510X98000926
- 3. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther Konrad V, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol [Internet]. 1999 Dec;46(6):860–6. Available from: http://doi.wiley.com/10.1002/1531-8249(199912)46:6%3C860::AID-ANA8%3E3.0.CO;2-M
- 4. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol [Internet]. 1999 Aug;158(2):328–37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10415140
- 5. Viles JH. Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, zinc and iron in Alzheimer’s, Parkinson’s and prion diseases. Coord Chem Rev [Internet]. 2012 Oct;256(19–20):2271–84. Available from: http://dx.doi.org/10.1016/j.ccr.2012.05.003
- 6. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol [Internet]. 2006 Apr;572(2):477–92. Available from: http://doi.wiley.com/10.1113/jphysiol.2005.103754
- 7. Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, et al. A Ganglioside-induced Toxic Soluble Abeta Assembly: Its Enhanced Formation from Abeta Bearing the Arctic Mutation. J Biol Chem [Internet]. 2007 Jan 26;282(4):2646–55. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M606202200
- 8. Neniskyte U, Neher JJ, Brown GC. Neuronal Death Induced by Nanomolar Amyloid Is Mediated by Primary Phagocytosis of Neurons by Microglia. J Biol Chem [Internet]. 2011 Nov 18;286(46):39904–13. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M111.267583
- 9. Lacor PN, Buniel MC, Furlow PW, Sanz Clemente A, Velasco PT, Wood M, et al. A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer’s Disease. J Neurosci [Internet]. 2007 Jan 24;27(4):796–807. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.3501-06.2007
- 10. Walsh DM. Certain Inhibitors of Synthetic Amyloid β-Peptide (Aβ) Fibrillogenesis Block Oligomerization of Natural A and Thereby Rescue Long-Term Potentiation. J Neurosci [Internet]. 2005 Mar 9;25(10):2455–62. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.4391-04.2005
- 11. Kepp KP. Bioinorganic Chemistry of Alzheimer’s Disease. Chem Rev [Internet]. 2012 Oct 10;112(10):5193–239. Available from: http://pubs.acs.org/doi/abs/10.1021/cr300009x
- 12. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Aβ oligomers. FEBS J [Internet]. 2010 Mar;277(6):1348–58. Available from: http://doi.wiley.com/10.1111/j.1742-4658.2010.07568.x
- 13. Hu X, Crick SL, Bu G, Frieden C, Pappu R V, Lee J-M. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci [Internet]. 2009 Dec 1;106(48):20324–9. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.0911281106
- 14. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer’s betapeptide from biological fluids. Nature. 1992;(359):325–327. pmid:1406936
- 15. Cirrito JR, May PC, O’Dell MA, Taylor JW, Parsadanian M, Cramer JW, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci [Internet]. 2003 Oct 1;23(26):8844–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14523085
- 16. Hane F, Leonenko Z. Effect of Metals on Kinetic Pathways of Amyloid-β Aggregation. Biomolecules [Internet]. 2014 Jan 10;4(1):101–16. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4030978&tool=pmcentrez&rendertype=abstract
- 17. Faller P, Hureau C, Berthoumieu O. Role of Metal Ions in the Self-assembly of the Alzheimer’s Amyloid-β Peptide. Inorg Chem [Internet]. 2013 Nov 4;52(21):12193–206. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23607830
- 18. Wärmländer S, Tiiman A, Abelein A, Luo J, Jarvet J, Söderberg KL, et al. Biophysical Studies of the Amyloid β-Peptide: Interactions with Metal Ions and Small Molecules. ChemBioChem [Internet]. 2013 Sep 23;14(14):1692–704. Available from: http://doi.wiley.com/10.1002/cbic.201300262
- 19. Ha C, Ryu J, Park CB. Metal Ions Differentially Influence the Aggregation and Deposition of Alzheimer’s β-Amyloid on a Solid Template. Biochemistry [Internet]. 2007 May;46(20):6118–25. Available from: http://pubs.acs.org/doi/abs/10.1021/bi7000032
- 20. Pedersen JT, Østergaard J, Rozlosnik N, Gammelgaard B, Heegaard NHH. Cu(II) mediates kinetically distinct, non-amyloidogenic aggregation of amyloid-β peptides. J Biol Chem. 2011;286(30):26952–63. pmid:21642429
- 21. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, et al. Morphology and toxicity of Abeta-(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer’s disease. J Biol Chem [Internet]. 1996 Aug 23;271(34):20631–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8702810
- 22. Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S, Glabe CG. Soluble Amyloid Aβ(1–40) Exists as a Stable Dimer at Low Concentrations. J Biol Chem [Internet]. 1997 Aug 22;272(34):21037–44. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.272.34.21037
- 23. Alies B, Renaglia E, Bal W, Faller P, Hureau C. Cu(II) Affinity for the Alzheimer’s Peptide: Tyrosine Fluorescence Studies Revisited. Anal Chamistry. 2013;85:1501–8.
- 24. Young TR, Kirchner A, Wedd AG, Xiao Z. An integrated study of the affinities of the Ab16 peptide for Cu(I) and Cu(II): implications for the catalytic production of reactive oxygen species oxygen species. Metallomics [Internet]. 2014 Jan 24;6(3):505–17. Available from: http://xlink.rsc.org/?DOI=C4MT00001C
- 25. Drew SC, Barnham KJ. The Heterogeneous Nature of Cu 2+ Interactions with Alzheimer’s Amyloid-β Peptide. Acc Chem Res [Internet]. 2011 Nov 15;44(11):1146–55. Available from: http://pubs.acs.org/doi/abs/10.1021/ar200014u
- 26. Hureau C. Coordination of redox active metal ions to the amyloid precursor protein and to amyloid-β peptides involved in Alzheimer disease. Coord Chem Rev [Internet]. 2012 Oct;256(19–20):2164–74. Available from: http://dx.doi.org/10.1016/j.ccr.2012.03.037
- 27. Branch T, Girvan P, Barahona M, Ying L. Introduction of a Fluorescent Probe to Amyloid-β to Reveal Kinetic Insights into Its Interactions with Copper(II). Angew Chemie Int Ed [Internet]. 2015 Jan 19;54(4):1227–30. Available from: http://doi.wiley.com/10.1002/anie.201408810
- 28. Bin Y, Chen S, Xiang J. pH-dependent kinetics of copper ions binding to amyloid-β peptide. J Inorg Biochem [Internet]. 2013 Feb;119:21–7. Available from: http://dx.doi.org/10.1016/j.jinorgbio.2012.10.013
- 29. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimers Aβ peptides. JBIC J Biol Inorg Chem [Internet]. 2004 Dec 3;9(8):954–60. Available from: http://link.springer.com/10.1007/s00775-004-0602-8
- 30. McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, et al. The Caenorhabditis elegans Aβ 1–42 Model of Alzheimer Disease Predominantly Expresses Aβ 3–42. J Biol Chem [Internet]. 2009 Aug 21;284(34):22697–702. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.C109.028514
- 31. Pedersen JT, Teilum K, Heegaard NHH, Østergaard J, Adolph H-W, Hemmingsen L. Rapid Formation of a Preoligomeric Peptide–Metal–Peptide Complex Following Copper(II) Binding to Amyloid β Peptides. Angew Chemie Int Ed [Internet]. 2011;50(11):2532–5. Available from: http://onlinelibrary.wiley.com/doi/10.1002/anie.201006335/abstract%5Cnhttp://onlinelibrary.wiley.com/store/10.1002/anie.201006335/asset/2532_ftp.pdf?v=1&t=i7lzkpr4&s=a51216d892579b90bf0df1b68751f74db5337565
- 32. Sarell CJ, Syme CD, Rigby SEJ, Viles JH. Copper(II) Binding to Amyloid-β Fibrils of Alzheimer’s Disease Reveals a Picomolar Affinity: Stoichiometry and Coordination Geometry Are Independent of Aβ Oligomeric Form. Biochemistry [Internet]. 2009 May 26;48(20):4388–402. Available from: http://pubs.acs.org/doi/abs/10.1021/bi900254n
- 33. Jiang D, Zhang L, Grant GPG, Dudzik CG, Chen S, Patel S, et al. The Elevated Copper Binding Strength of Amyloid-β Aggregates Allows the Sequestration of Copper from Albumin: A Pathway to Accumulation of Copper in Senile Plaques. Biochemistry [Internet]. 2013 Jan 22;52(3):547–56. Available from: http://pubs.acs.org/doi/abs/10.1021/bi301053h
- 34. Garai K, Frieden C. Quantitative analysis of the time course of Aβ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Aβ. Proc Natl Acad Sci [Internet]. 2013 Feb 26;110(9):3321–6. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1222478110
- 35. Syme CD, Nadal RC, Rigby SEJ, Viles JH. Copper Binding to the Amyloid-β (Aβ) Peptide Associated with Alzheimer’s Disease: Folding, Coordination, Geometry, pH Dependance, Stoichiometry, and Affinity of A -β(1–28): Insights from a Range of Comlementary Spectroscopic Techniques. J Biol Chem [Internet]. 2004 Apr 30;279(18):18169–77. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M313572200
- 36. Karr JW, Szalai VA. Role of Aspartate-1 in Cu(II) Binding to the Amyloid-β Peptide of Alzheimer’s Disease. J Am Chem Soc [Internet]. 2007 Apr;129(13):3796–7. Available from: http://pubs.acs.org/doi/abs/10.1021/ja068952d
- 37. Sarell CJ, Wilkinson SR, Viles JH. Substoichiometric Levels of Cu2+ Ions Accelerate the Kinetics of Fiber Formation and Promote Cell Toxicity of Amyloid-β from Alzheimer Disease. J Biol Chem [Internet]. 2010 Dec 31;285(53):41533–40. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M110.171355
- 38. Smith DP, Ciccotosto GD, Tew DJ, Fodero-Tavoletti MT, Johanssen T, Masters CL, et al. Concentration Dependent Cu 2+ Induced Aggregation and Dityrosine Formation of the Alzheimer’s Disease Amyloid-β Peptide. Biochemistry [Internet]. 2007 Mar;46(10):2881–91. Available from: http://pubs.acs.org/doi/abs/10.1021/bi0620961
- 39. Yoshiike Y. New Insights on How Metals Disrupt Amyloid-beta Aggregation and Their Effects on Amyloid-beta Cytotoxicity. J Biol Chem [Internet]. 2001 Aug 17;276(34):32293–9. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M010706200
- 40. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A Role for Synaptic Zinc in Activity-Dependent A Oligomer Formation and Accumulation at Excitatory Synapses. J Neurosci [Internet]. 2009 Apr 1;29(13):4004–15. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.5980-08.2009
- 41. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, et al. Oligomeric amyloid associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci [Internet]. 2009 Mar 10;106(10):4012–7. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.0811698106
- 42. Arellano JI, Benavides-Piccione R, Defelipe J, Yuste R. Ultrastructure of dendritic spines: correlation between synaptic and spine morphologies. Front Neurosci. 2007;1(1):131–43. pmid:18982124
- 43. Chyung ASC, Greenberg BD, Cook DG, Doms RW, Lee VM-Y. Novel β-Secretase Cleavage of β-Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells. J Cell Biol [Internet]. 1997 Aug 11;138(3):671–80. Available from: http://www.jcb.org/lookup/doi/10.1083/jcb.138.3.671
- 44. Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, et al. Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci U S A [Internet]. 1997 Apr 15;94(8):3748–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9109049%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=20512&tool=pmcentrez&rendertype=abstract
- 45. Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem [Internet]. 1994 Jul 1;269(26):17386–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8021238
- 46. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, et al. Neurotoxic, Redox-competent Alzheimer’s -Amyloid Is Released from Lipid Membrane by Methionine Oxidation. J Biol Chem [Internet]. 2003 Oct 31;278(44):42959–65. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M305494200
- 47. Crimins JL, Pooler A, Polydoro M, Luebke JI, Spires-Jones TL. The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer’s disease. Ageing Res Rev [Internet]. 2013 Jun;12(3):757–63. Available from: http://dx.doi.org/10.1016/j.arr.2013.03.002
- 48. Johnston I. The chaos within: Exploring noise in cellular biology. Significance [Internet]. 2012 Aug;9(4):17–21. Available from: http://doi.wiley.com/10.1111/j.1740-9713.2012.00586.x
- 49. Shahrezaei V, Swain PS. The stochastic nature of biochemical networks. Curr Opin Biotechnol [Internet]. 2008 Aug;19(4):369–74. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0958166908000815
- 50. Maheshri N, O’Shea EK. Living with Noisy Genes: How Cells Function Reliably with Inherent Variability in Gene Expression. Annu Rev Biophys Biomol Struct [Internet]. 2007 Jun;36(1):413–34. Available from: http://www.annualreviews.org/doi/abs/10.1146/annurev.biophys.36.040306.132705
- 51. Gillespie DT. A rigorous derivation of the chemical master equation. Phys A Stat Mech its Appl [Internet]. 1992 Sep;188(1–3):404–25. Available from: http://linkinghub.elsevier.com/retrieve/pii/037843719290283V
- 52. Nasica-Labouze J, Nguyen PH, Sterpone F, Berthoumieu O, Buchete N-V, Coté S, et al. Amyloid β Protein and Alzheimer’s Disease: When Computer Simulations Complement Experimental Studies. Chem Rev [Internet]. 2015 May 13;115(9):3518–63. Available from: http://pubs.acs.org/doi/abs/10.1021/cr500638n
- 53. Pallitto MM, Murphy RM. A Mathematical Model of the Kinetics of β-Amyloid Fibril Growth from the Denatured State. Biophys J [Internet]. 2001 Sep;81(3):1805–22. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=11509390&retmode=ref&cmd=prlinks
- 54. Schreck JS, Yuan J. A Kinetic Study of Amyloid Formation: Fibril Growth and Length Distributions. 2013 Aug 23; Available from: http://arxiv.org/abs/1308.5161
- 55. Mo J-A, Lim J-H, Sul A-R, Lee M, Youn YC, Kim H-J. Cerebrospinal Fluid β-Amyloid1–42 Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis. PLoS One [Internet]. 2015;10(2):1–16. Available from: http://10.0.5.91/journal.pone.0116802%5Cnhttp://search.ebscohost.com/login.aspx?direct=true&db=a9h&AN=101318234&lang=es&site=ehost-live
- 56. Agarwal R. CSF tau and amyloid β42 levels in Alzheimer’s disease—A meta-analysis. Adv Alzheimer’s Dis [Internet]. 2012;1(3):30–44. Available from: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=25879&#abstract
- 57. Gu L, Guo Z. Alzheimer’s Aβ42 and Aβ40 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126(3):305–11. pmid:23406382
- 58. Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, et al. Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease. PLoS One. 2013;8(6):1–8.
- 59. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol [Internet]. 2002 Sep;59(9):1381–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12223024
- 60. Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, et al. Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease. J Exp Med [Internet]. 2015 Nov 16;212(12):2003–13. Available from: http://jem.rupress.org/content/early/2015/10/14/jem.20150892.long
- 61. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med [Internet]. 2016 Jun 1;8(6):595–608. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27025652
- 62. Kardos J, Kovács I, Hajós F, Kálmán M, Simonyi M. Nerve endings from rat brain tissue release copper upon depolarization. A possible role in regulating neuronal excitability. Neurosci Lett [Internet]. 1989 Aug;103(2):139–44. Available from: http://linkinghub.elsevier.com/retrieve/pii/030439408990565X
- 63. Hopt A, Korte S, Fink H, Panne U, Niessner R, Jahn R, et al. Methods for studying synaptosomal copper release. J Neurosci Methods [Internet]. 2003 Sep;128(1–2):159–72. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0165027003001730
- 64. Schlief ML, Craig AM, Gitlin JD. NMDA Receptor Activation Mediates Copper Homeostasis in Hippocampal Neurons. J Neurosci [Internet]. 2005 Jan 5;25(1):239–46. Available from: papers2://publication/doi/10.1523/JNEUROSCI.3699-04.2005
- 65. Nose Y, Wood LK, Kim B-E, Prohaska JR, Fry RS, Spears JW, et al. Ctr1 Is an Apical Copper Transporter in Mammalian Intestinal Epithelial Cells in Vivo That Is Controlled at the Level of Protein Stability. J Biol Chem [Internet]. 2010 Oct 15;285(42):32385–92. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M110.143826
- 66. Artells E, Palacios Ò, Capdevila M, Atrian S. In vivo -folded metal-metallothionein 3 complexes reveal the Cu-thionein rather than Zn-thionein character of this brain-specific mammalian metallothionein. FEBS J [Internet]. 2014 Mar;281(6):1659–78. Available from: http://doi.wiley.com/10.1111/febs.12731
- 67. Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, Calabrese L, et al. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer’s disease patients. BioMetals [Internet]. 2008 Jun 30;21(3):367–72. Available from: http://link.springer.com/10.1007/s10534-007-9125-4
- 68. Nischwitz V, Berthele A, Michalke B. Speciation analysis of selected metals and determination of their total contents in paired serum and cerebrospinal fluid samples: An approach to investigate the permeability of the human blood-cerebrospinal fluid-barrier. Anal Chim Acta [Internet]. 2008 Oct;627(2):258–69. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0003267008014931
- 69. Fawzi NL, Ying J, Torchia D a., Clore GM. Kinetics of Amyloid β Monomer-to-Oligomer Exchange by NMR Relaxation. J Am Chem Soc [Internet]. 2010 Jul 28;132(29):9948–51. Available from: http://pubs.acs.org/doi/abs/10.1021/ja1048253
- 70. Murphy RM. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. Biochim Biophys Acta—Biomembr [Internet]. 2007 Aug;1768(8):1923–34. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0005273606004913
- 71. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, et al. Amyloid-β Peptide (Aβ) Neurotoxicity Is Modulated by the Rate of Peptide Aggregation: A Dimers and Trimers Correlate with Neurotoxicity. J Neurosci [Internet]. 2008 Nov 12;28(46):11950–8. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.3916-08.2008
- 72. Singh I, Sagare AP, Coma M, Perlmutter D, Gelein R, Bell RD, et al. Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearance. Proc Natl Acad Sci [Internet]. 2013 Sep 3;110(36):14771–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23959870
- 73. Atwood CS, Moir RD, Huang XD, Scarpa RC, Bacarra NME, Romano DM, et al. Dramatic aggregation of Alzheimer—Aβ by Cu(II) is induced by conditions representing physiological conditions. J Biol Chem. 1998;273(21):12817–26. pmid:9582309
- 74. Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, et al. Copper-mediated Amyloid-beta Toxicity Is Associated with an Intermolecular Histidine Bridge. J Biol Chem [Internet]. 2006 Jun 2;281(22):15145–54. Available from: http://www.jbc.org/content/281/22/15145%5Cnhttp://www.jbc.org/content/281/22/15145.full.pdf%5Cnhttp://www.jbc.org/content/281/22/15145.long%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/16595673
- 75. Hortschansky P, Schroeckh V, Christopeit T, Zandomeneghi G, Fändrich M. The aggregation kinetics of Alzheimer’s beta-amyloid peptide is controlled by stochastic nucleation. Protein Sci [Internet]. 2005 Jul;14(7):1753–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15937275
- 76. Alvarez VA, Sabatini BL. Anatomical and Physiological Plasticity of Dendritic Spines. Annu Rev Neurosci [Internet]. 2007 Jul;30(1):79–97. Available from: http://www.annualreviews.org/doi/abs/10.1146/annurev.neuro.30.051606.094222
- 77. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martin RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibriliary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985;4(11):2757–63. pmid:4065091
- 78. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. PNAS. 1985;82(12):4245–9. pmid:3159021
- 79. Pellarin R, Caflisch A. Interpreting the Aggregation Kinetics of Amyloid Peptides. J Mol Biol [Internet]. 2006;360(4):882–92. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022283606006152
- 80. Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM, et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol [Internet]. 2006 Apr;32(2):103–18. Available from: http://doi.wiley.com/10.1111/j.1365-2990.2006.00696.x
- 81. Mital M, Wezynfeld NE, Frączyk T, Wiloch MZ, Wawrzyniak UE, Bonna A, et al. A Functional Role for Aβ in Metal Homeostasis? N-Truncation and High-Affinity Copper Binding. Angew Chemie Int Ed [Internet]. 2015 Sep 1;54(36):10460–4. Available from: http://doi.wiley.com/10.1002/anie.201502644
- 82. Wezynfeld NE, Stefaniak E, Stachucy K, Drozd A, Płonka D, Drew SC, et al. Resistance of Cu(Aβ4–16) to Copper Capture by Metallothionein-3 Supports a Function for the Aβ4–42 Peptide as a Synaptic Cu II Scavenger. Angew Chemie Int Ed [Internet]. 2016 Jul 11;55(29):8235–8. Available from: http://doi.wiley.com/10.1002/anie.201511968
- 83. Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S, et al. N-truncated amyloid β (Aβ) 4–42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol [Internet]. 2013 Aug 18;126(2):189–205. Available from: http://link.springer.com/10.1007/s00401-013-1129-2